{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:12:02Z","timestamp":1778238722030,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"DOI":"10.7759\/cureus.108480","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:04:33Z","timestamp":1778238273000},"source":"Crossref","is-referenced-by-count":0,"title":["Complex Challenges in ANCA-Associated Vasculitis: A Case of COVID-19, Cytomegalovirus Pneumonitis, and Hemorrhagic Cholecystitis Following Rituximab Therapy"],"prefix":"10.7759","author":[{"given":"Fatema","family":"Ezzy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Reyes Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Jinjolava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci AS","year":"1983","unstructured":"Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983, 98:76-85. 10.7326\/0003-4819-98-1-76","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"2","author":"Walton EW","year":"1958","unstructured":"Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958, 2:265-70. 10.1136\/bmj.2.5091.265","journal-title":"Br Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann O","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, et al.. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011, 70:488-94. 10.1136\/ard.2010.137778","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones RB","year":"2015","unstructured":"Jones RB, Furuta S, Tervaert JW, et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015, 74:1178-82. 10.1136\/annrheumdis-2014-206404","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep304","article-title":"Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa","volume":"48","author":"Mohammad AJ","year":"2009","unstructured":"Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009, 48:1560-5. 10.1093\/rheumatology\/kep304","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little MA","year":"2010","unstructured":"Little MA, Nightingale P, Verburgh CA, et al.. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010, 69:1036-43. 10.1136\/ard.2009.109389","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2020.01.002","article-title":"Treatment and its side effects in ANCA-associated vasculitides - study based on POLVAS registry data","volume":"65","author":"Biedro\u0144 G","year":"2020","unstructured":"Biedro\u0144 G, W\u0142udarczyk A, Wawrzycka-Adamczyk K, et al.. Treatment and its side effects in ANCA-associated vasculitides - study based on POLVAS registry data. Adv Med Sci. 2020, 65:156-62. 10.1016\/j.advms.2020.01.002","journal-title":"Adv Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera A","year":"2022","unstructured":"Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022, 23:3636. 10.3390\/ijms23073636","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref11","unstructured":"Hospitalized Adults. Therapeutic Management. COVID-19 Treatment Guidelines. Accessed: February 9, 2024: https:\/\/adsp.nm.org\/uploads\/1\/4\/3\/0\/143064172\/nih_hosp_adult_guideline.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman P","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, et al.. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017, 64:87-91. 10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac186","article-title":"ANCA-associated vasculitis flare might be provoked by COVID-19 infection: a case report and a review of the literature","volume":"15","author":"Ozcan S","year":"2022","unstructured":"Ozcan S, Sonmez O, Karaca C, Ozdede A, Seyahi N. ANCA-associated vasculitis flare might be provoked by COVID-19 infection: a case report and a review of the literature. Clin Kidney J. 2022, 15:1987-95. 10.1093\/ckj\/sfac186","journal-title":"Clin Kidney J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088302","article-title":"Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients","volume":"68","author":"Charlier C","year":"2009","unstructured":"Charlier C, Henegar C, Launay O, et al.. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009, 68:658-63. 10.1136\/ard.2008.088302","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot K","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, et al.. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005, 52:2461-9. 10.1002\/art.21142","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218705","article-title":"Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"14","author":"Morishita M","year":"2019","unstructured":"Morishita M, Sada KE, Matsumoto Y, et al.. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2019, 14:e0218705. 10.1371\/journal.pone.0218705","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14444","article-title":"Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0narrative review","volume":"25","author":"Leong A","year":"2022","unstructured":"Leong A, Fong W. Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0narrative review. Int J Rheum Dis. 2022, 25:1357-67. 10.1111\/1756-185X.14444","journal-title":"Int J Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104849","article-title":"Subclinical CMV viremia is associated with increased nosocomial infections and prolonged hospitalization in patients with systemic autoimmune diseases","volume":"140","author":"Maksimowicz-McKinnon K","year":"2021","unstructured":"Maksimowicz-McKinnon K, Zhou J, Hudy J, Hegab S, McKinnon JE. Subclinical CMV viremia is associated with increased nosocomial infections and prolonged hospitalization in patients with systemic autoimmune diseases. J Clin Virol. 2021, 140:104849. 10.1016\/j.jcv.2021.104849","journal-title":"J Clin Virol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton CN","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A. The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018, 102:900-31. 10.1097\/TP.0000000000002191","journal-title":"Transplantation"},{"key":"ref20","article-title":"Immune reconstitution inflammatory syndrome","author":"Thapa S","year":"2026","unstructured":"Thapa S, Shrestha U. Immune reconstitution inflammatory syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2000.00012.x","article-title":"Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy","volume":"1","author":"French MA","year":"2000","unstructured":"French MA, Lenzo N, John M, et al.. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000, 1:107-15. 10.1046\/j.1468-1293.2000.00012.x","journal-title":"HIV Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070797","article-title":"Anti-cytomegalovirus therapy: whether and when to initiate, those are the questions","volume":"15","author":"Aoyama Y","year":"2022","unstructured":"Aoyama Y, Sugiyama S, Yamamoto T. Anti-cytomegalovirus therapy: whether and when to initiate, those are the questions. Pharmaceuticals (Basel). 2022, 15:10.3390\/ph15070797","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.003","article-title":"Refractory rheumatoid vasculitis complicated by cytomegalovirus reactivation as a manifestation of immune reconstitution inflammatory syndrome","volume":"6","author":"Katsuta M","year":"2020","unstructured":"Katsuta M, Shiohara T, Asahina A. Refractory rheumatoid vasculitis complicated by cytomegalovirus reactivation as a manifestation of immune reconstitution inflammatory syndrome. JAAD Case Rep. 2020, 6:652-5. 10.1016\/j.jdcr.2020.05.003","journal-title":"JAAD Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad090","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 Guidelines\/Recommendations","volume":"38","author":"Casal Moura M","year":"2023","unstructured":"Casal Moura M, Gauckler P, Anders HJ, et al.. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 Guidelines\/Recommendations. Nephrol Dial Transplant. 2023, 38:2637-51. 10.1093\/ndt\/gfad090","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366786-complex-challenges-in-anca-associated-vasculitis-a-case-of-covid-19-cytomegalovirus-pneumonitis-and-hemorrhagic-cholecystitis-following-rituximab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:04:36Z","timestamp":1778238276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366786-complex-challenges-in-anca-associated-vasculitis-a-case-of-covid-19-cytomegalovirus-pneumonitis-and-hemorrhagic-cholecystitis-following-rituximab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.108480","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}